Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America

Lyon, France (ots/PRNewswire) -

- Six Million Doses of Stamaril(TM) Vaccine Shipped in Record
Time to Brazil and Paraguay

Sanofi Pasteur, the vaccines division of the Sanofi-aventis
Group, announced today that six million doses of Stamaril(TM)(1)
yellow fever vaccine have been shipped upon UNICEF's request to
respond to the yellow fever epidemic in Latin America.

Brazil received four million doses of Stamaril(TM) vaccine early
February and an additional two million doses were shipped to Paraguay
over the weekend in response to urgent requests from Health
Authorities.

"Sanofi Pasteur mobilized its teams to make this public health
emergency a priority," said Wayne Pisano, President and Chief
Executive Officer of Sanofi Pasteur. "This ability to respond to an
emergency in record time illustrates the company's commitment to
global health."

The yellow fever vaccine that was provided to Brazil and Paraguay
is part of the UNICEF vaccine stockpile which is reserved for
outbreak responses. Sanofi Pasteur is currently the only vaccine
supplier to the UNICEF yellow fever vaccine stockpile.

Sanofi Pasteur is the largest provider of yellow fever vaccine
worldwide with 200 million doses of vaccine provided to 150 countries
over the past 20 years.

About yellow fever

Yellow fever is a viral disease that occurs in both rural and
urban areas in Africa and South America. There is no treatment for
yellow fever, only prevention by immunization. More than 200,000
people contract the disease and 30,000 people die from it each year.
According to the WHO, over 30 countries in Africa (with an estimated
population of 508 million) are at risk. In the Americas, yellow fever
is endemic in nine South American countries and in several Caribbean
islands.

About Sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company,
discovers, develops and distributes therapeutic solutions to improve
the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT:
SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of sanofi-aventis Group,
provided more than 1.6 billion doses of vaccine in 2007, making it
possible to immunize more than 500 million people across the globe. A
world leader in the vaccine industry, sanofi pasteur offers the
broadest range of vaccines protecting against 20 infectious diseases.
The company's heritage, to create vaccines that protect life, dates
back more than a century. Sanofi Pasteur is the largest company
entirely dedicated to vaccines. Every day, the company invests more
than EUR1 million in research and development. For more information,
please visit: http://www.sanofipasteur.com or
http://www.sanofipasteur.us

Forward Looking Statements

This press release contains forward-looking statements as defined
in the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include financial projections and estimates
and their underlying assumptions, statements regarding plans,
objectives, intentions and expectations with respect to future
events, operations, products and services, and statements regarding
future performance. Forward-looking statements are generally
identified by the words "expects," "anticipates," "believes,"
"intends," "estimates," "plans" and similar expressions. Although
sanofi-aventis' management believes that the expectations reflected
in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject
to various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of sanofi-aventis, that
could cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
those discussed or identified in the public filings with the SEC and
the AMF made by sanofi-aventis, including those listed under "Risk
Factors" and "Cautionary Statement Regarding Forward-Looking
Statements" in Sanofi-aventis' annual report on Form 20-F for the
year ended December 31, 2006. Other than as required by applicable
law, sanofi-aventis does not undertake any obligation to update or
revise any forward-looking information or statements.

(1) Stamaril is a trademark of Institut Pasteur

ots Originaltext: sanofi-aventis Group
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Sanofi Pasteur, Pascal Barollier, Media Relations, Tel:
+33-4-37-37-51-41, pascal.barollier@sanofipasteur.com; Sanofi
Pasteur, Len Lavenda, Media Relations US, Tel: +1-570-839-4446,
len.lavenda@sanofipasteur.com; Media Relations: Tel.:
+33-4-37-37-50-38, Media Relations US: Tel.: +1-570-839-44